1. van der Knaap, Marjo S, Bugiani, Marianna, Abbink, Truus E M. . Vanishing white matter. In Handbook of clinical neurology, 204, 77-94. doi:10.1016/B978-0-323-99209-1.00015-6. https://pubmed.ncbi.nlm.nih.gov/39322396/
2. De Franco, Elisa, Caswell, Richard, Johnson, Matthew B, Ron, David, Hattersley, Andrew T. 2019. De Novo Mutations in EIF2B1 Affecting eIF2 Signaling Cause Neonatal/Early-Onset Diabetes and Transient Hepatic Dysfunction. In Diabetes, 69, 477-483. doi:10.2337/db19-1029. https://pubmed.ncbi.nlm.nih.gov/31882561/
3. Herstine, Jessica A, Chang, Pi-Kai, Chornyy, Sergiy, Bonkowsky, Joshua L, Bradbury, Allison M. 2024. Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease. In Molecular therapy : the journal of the American Society of Gene Therapy, 32, 1701-1720. doi:10.1016/j.ymthe.2024.03.034. https://pubmed.ncbi.nlm.nih.gov/38549375/
4. Wek, Ronald C, Anthony, Tracy G, Staschke, Kirk A. 2023. Surviving and Adapting to Stress: Translational Control and the Integrated Stress Response. In Antioxidants & redox signaling, 39, 351-373. doi:10.1089/ars.2022.0123. https://pubmed.ncbi.nlm.nih.gov/36943285/
5. Böck, Desirée, Revers, Ilma M, Bomhof, Anastasia S J, van Til, Niek P, Schwank, Gerald. 2024. In vivo base editing of a pathogenic Eif2b5 variant improves vanishing white matter phenotypes in mice. In Molecular therapy : the journal of the American Society of Gene Therapy, 32, 1328-1343. doi:10.1016/j.ymthe.2024.03.009. https://pubmed.ncbi.nlm.nih.gov/38454603/
智鼠故事 
